NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army ...

The research team focused on an enzyme called Vaccinia-H1-related phosphatase (VHR) due to its role in controlling how the immune system responds when sensing danger. Previous studies have shown that ...

The immune system typically can ramp up the body's defenses to clear out an invading threat without issue. Glitches can ...

One of the molecular fragments (pink) uncovered using fragment-based drug discovery is shown binding with an immune system enzyme called Vaccinia-H1-related phosphatase.

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

Calidi Biotherapeutics (NYSE American: CLDI) announced positive preclinical results for its systemic RTNova platform, demonstrating effective delive ...

(NYSE American: CLDI) announced positive preclinical results for its systemic RTNova platform, demonstrating effective delivery of transient gene therapy payloads to targeted tumors. The ...

Biotherapeutics announced promising preclinical results for its systemic RTNova platform. The platform has successfully delivered ...

Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced promising ...

Alignment with National Health Security Goals: GeoVax’s focus on U.S.-based vaccine production supports HHS’s priority of reducing dependency on foreign pharmaceutical supply chains, ensuring ...

Strengthening U.S. Biodefense. ATLANTA, GA - March 3, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in developing vaccines and immunotherapi ...